GLP-1 receptor agonist medications mimic the hormones naturally found in our gut to delay gastric emptying (slow down the rate at which food moves through our digestive tract, which keeps us feeling fuller for more extended periods)
N Engl J Med 2021;384:111324.ArticlePubMed 81
Current NICE guidance (NG49) does not yet include specific recommendations for GLP-1 use in fatty liver disease outside the context of diabetes or obesity management
Are you experiencing appetite suppression
Someone in the group accused us of excluding everyone else and the reality is we didntWhen I first read that message, it bothered me, but I was able to let go of it really quickly and kind of not let it affect me. (P2, male, obesity)
Non-responders had higher baseline ALT levels (p=0.03) compared to responders and exhibited higher levels of triglycerides (p=0.001), HOMA-IR (p=0.026), and ALT (p=0.049) levels at the trial endpoint